B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Intercept Pharma (ICPT) today and set a price target of $158.00. The company’s shares closed last Friday at $79.19.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 17.9% and a 49.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals, Arrowhead Pharmaceuticals, and Spectrum Pharmaceuticals.
Intercept Pharma has an analyst consensus of Strong Buy, with a price target consensus of $148.77, an 85.9% upside from current levels. In a report issued on May 11, Needham also assigned a Buy rating to the stock with a $150.00 price target.
See today’s analyst top recommended stocks >>
Based on Intercept Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $72.65 million and GAAP net loss of $92.98 million. In comparison, last year the company earned revenue of $52.25 million and had a GAAP net loss of $90.27 million.
Based on the recent corporate insider activity of 104 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ICPT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.